These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36918269)

  • 21. [Are phyllanthus species effective in hepatitis B?].
    Rakowitz B
    Dtsch Med Wochenschr; 2011 Jul; 136(28-29):1460. PubMed ID: 21732258
    [No Abstract]   [Full Text] [Related]  

  • 22. High dose lamivudine and hepatitis B.
    Musher DR; Wasser WG; Saggi SJ
    Am J Gastroenterol; 1999 Nov; 94(11):3372. PubMed ID: 10566751
    [No Abstract]   [Full Text] [Related]  

  • 23. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Biomarkers in Guiding Cure of Viral Hepatitis B.
    Buti M; Riveiro-Barciela M; Rodríguez-Frías F; Tabernero D; Esteban R
    Semin Liver Dis; 2020 Feb; 40(1):49-60. PubMed ID: 31805583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New concepts regarding finite oral antiviral therapy for HBeAg-negative chronic hepatitis B.
    Papatheodoridi M; Papatheodoridis G
    J Hepatol; 2021 Dec; 75(6):1495-1496. PubMed ID: 34171438
    [No Abstract]   [Full Text] [Related]  

  • 26. [Different treatment strategies in patients with HBeAg-positive and negative chronic hepatitis B].
    Zhang MY; Chen SY; Sun YM; You H
    Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):238-241. PubMed ID: 37137847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.
    Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F
    J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can we cure hepatitis B virus with novel direct-acting antivirals?
    Martinez MG; Villeret F; Testoni B; Zoulim F
    Liver Int; 2020 Feb; 40 Suppl 1():27-34. PubMed ID: 32077597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HBV RNA, Hepatitis B Core-Related Antigen, and Quantitative Hepatitis B Surface Antigen Biomarkers to Predict Outcome of Antiviral Therapy.
    Debnath P; Rathi P
    Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2680-2681. PubMed ID: 33387671
    [No Abstract]   [Full Text] [Related]  

  • 30. Which Is More Clinically Relevant: End-of-Treatment or Off-Treatment Predictors of Hepatitis B Relapse and Surface Antigen Loss?
    Zheng D; Fang Z; Sun J
    Gastroenterology; 2024 Jun; 166(6):1193-1194. PubMed ID: 37890561
    [No Abstract]   [Full Text] [Related]  

  • 31. Hepatitis B Surface Antigen Kinetics After Tenofovir Withdrawal in Chronic Hepatitis B.
    Hsu CE; Liaw YF
    Am J Gastroenterol; 2024 Feb; 119(2):389-390. PubMed ID: 38305791
    [No Abstract]   [Full Text] [Related]  

  • 32. [A 2020 update on the progress of treatment and new drug clinical trials for hepatitis B].
    Jia JD; Niu JQ; You H; Kong YY; Hou JL
    Zhonghua Gan Zang Bing Za Zhi; 2021 Feb; 29(2):97-101. PubMed ID: 33685074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Results of 2 years of interferon treatment in HBeAg positive chronic hepatitis B].
    Hu LH; Long XZ; Tang CL
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):940-1. PubMed ID: 20038338
    [No Abstract]   [Full Text] [Related]  

  • 34. Hepatitis B viral factors and treatment responses in chronic hepatitis B.
    Lin CL; Kao JH
    J Formos Med Assoc; 2013 Jun; 112(6):302-11. PubMed ID: 23787007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Application of the new serum markers in the research and development of innovative hepatitis B drugs].
    Lu FM; Wang J; Chen XM; Zhang XX; Zhang WH; Xu XY; Jia JD; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):649-653. PubMed ID: 32911901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection.
    Hu Y; Sun F; Yuan Q; Du J; Hu L; Gu Z; Zhou Q; Du X; He S; Sun Y; Wang Q; Fan L; Wang L; Qin S; Chen S; Li J; Wu W; Mao J; Zhou Y; Zhou Q; Zhang G; Ding CZ
    Bioorg Med Chem Lett; 2022 Nov; 75():128977. PubMed ID: 36089112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lamivudine treatment consensus from relative experts].
    Lamivudine Clinical Practice Group
    Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):157-8. PubMed ID: 12108391
    [No Abstract]   [Full Text] [Related]  

  • 38. Peginterferon for chronic hepatitis B: predicting success with on-treatment benchmarks.
    Moucari R
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1474-5. PubMed ID: 20796141
    [No Abstract]   [Full Text] [Related]  

  • 39. Advances in new antivirals for chronic hepatitis B.
    Tang Y; Liang H; Zeng G; Shen S; Sun J
    Chin Med J (Engl); 2022 Feb; 135(5):571-583. PubMed ID: 35120358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controversies in Treating Chronic Hepatitis B virus: The Role of Hepatitis B Virus DNA and Surface Antigen Titer.
    Huang DQ; Kew GS; Lim SG
    Clin Liver Dis; 2021 Nov; 25(4):763-784. PubMed ID: 34593152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.